1.Recurrent follicular dendritic cell sarcoma in abdomen: report of a case.
Jing LIU ; Rui ZHANG ; Zheng-long ZHU ; Peng CAO ; Xia LI ; Ping ZHOU ; Wei ZHANG
Chinese Journal of Pathology 2010;39(10):709-710
Abdominal Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
secondary
;
surgery
;
Dendritic Cell Sarcoma, Follicular
;
drug therapy
;
metabolism
;
pathology
;
surgery
;
Dendritic Cell Sarcoma, Interdigitating
;
metabolism
;
pathology
;
Diagnosis, Differential
;
Female
;
Gastrointestinal Stromal Tumors
;
metabolism
;
pathology
;
Histiocytoma, Malignant Fibrous
;
metabolism
;
pathology
;
Humans
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Omentum
;
Peritoneal Neoplasms
;
secondary
;
Receptor, Epidermal Growth Factor
;
metabolism
;
Receptors, Complement 3b
;
metabolism
;
Receptors, Complement 3d
;
metabolism
2.Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Ah Young LEEM ; Han Sang KIM ; Byung Woo YOO ; Beo Deul KANG ; Min Hwan KIM ; Sun Young RHA ; Hyo Song KIM
The Korean Journal of Internal Medicine 2014;29(2):246-249
Ifosfamide-induced Fanconi syndrome is a rare complication that typically occurs in young patients due to a cumulative dose of ifosfamide > 40-60 g/m2, a reduction in kidney mass, or concurrent cisplatin treatment. It is usually characterized by severe and fatal progression accompanied by type II proximal renal tubular dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and metabolic acidosis. Diabetes insipidus is also a rare complication of ifosfamide-induced renal disease. We herein describe a case involving a 61-year-old man who developed ifosfamide-induced Fanconi syndrome accompanied by diabetes insipidus only a few days after the first round of chemotherapy. He had no known risk factors. In addition, we briefly review the mechanisms and possible therapeutic options for this condition based on other cases in the literature. Patients who receive ifosfamide must be closely monitored for renal impairment to avoid this rare but fatal complication.
Acidosis/chemically induced
;
Antineoplastic Agents, Alkylating/*adverse effects
;
Chemotherapy, Adjuvant
;
Diabetes Insipidus/*chemically induced/diagnosis/therapy
;
Fanconi Syndrome/*chemically induced/diagnosis/therapy
;
Fatal Outcome
;
Histiocytoma, Malignant Fibrous/*drug therapy/pathology
;
Humans
;
Ifosfamide/*adverse effects
;
Male
;
Middle Aged
;
Neoadjuvant Therapy/*adverse effects
;
Time Factors